NOCDURNA for Women: Four US Label and Availability Checks

Before acting on an older NOCDURNA advertisement or study, check what product is being discussed and whether a pharmacy can supply it.

Check the US marketing status first

On October 16, 2026, Drugs@FDA listed both NOCDURNA strengths, 0.0277 mg and 0.0553 mg, as discontinued under application 022517.¹

That entry identifies a marketing status; it does not give this product’s reason for discontinuation. FDA’s definition includes several circumstances, so the listing alone should not be interpreted as a safety withdrawal.²

Ask the pharmacist to identify any proposed replacement by its full name, route and strength. A remaining online label is not proof that a product is being supplied. Confirm the available option with the prescriber before changing treatment.

Check the formulation and the reason for night trips

The US label specifies 27.7 micrograms of desmopressin acetate, equivalent to 25 micrograms of desmopressin, for women. It is a sublingual formulation for adults waking at least twice nightly because of nocturnal polyuria, meaning excess nighttime urine production. The label calls for confirming that diagnosis with a 24-hour urine collection if not already obtained.³

Have the clinician explain the measured pattern and the proposed preparation. Do not convert a tablet or nasal-spray prescription yourself.

Compare the benefit with placebo, not just the starting symptoms

The 2013 US–Canadian trial⁴ randomized 268 women; the full efficacy analysis included 261 aged 19–87. Over three months, the adjusted average reduction was 1.46 night trips with 25-microgram desmopressin versus 1.24 with placebo: an additional 0.22 trips per night, statistically significant. At three months, the time until the first night trip was 49 minutes longer than with placebo.⁴

Ferring funded the study, supplied tablets and supported writing assistance; two authors worked for Ferring. Screening excluded women with renal impairment or severe daytime voiding problems; treatment lasted three months. Three treated women had sodium below 130 mmol/L, including two enrolled despite low starting sodium.⁴

Use the expected change to agree on a review target: fewer trips, a longer first sleep period, or both. Record the starting pattern before treatment changes.

Arrange sodium checks and a medicine review

The label requires normal sodium before starting or restarting, testing within one week and at about one month, then periodically; monitoring is more frequent at 65 or older or with added risks. It contraindicates use with loop diuretics or systemic or inhaled glucocorticoids, and in conditions including heart failure, uncontrolled hypertension and eGFR below 50. Fluid intake must be minimized from one hour before until eight hours after a dose. Severe low sodium can cause seizures, coma or death.³

A 2025 observational study⁵ examined 6,745 desmopressin-tablet users in Sweden, Denmark and Germany using 2016–2021 records. Diagnosed low-sodium event rates were higher during the first month than later. Patients and data sources differed, preventing a direct treatment comparison; this does not establish an individual’s risk. Ferring sponsored the study, and authors disclosed company employment or consultancy.⁵

Ask who orders and reviews blood tests, what to do during vomiting or diarrhea, and which symptoms require urgent contact. Take inhalers, pain relievers and antidepressants on the medicine list, alongside prescriptions from other clinics.

Bring the nighttime pattern

“Your Three-Day Read” in Laugh, Sneeze, Jump records drinks, bathroom times, leaks, activities and urgency, including overnight entries. A measured urine-volume chart may require additional instructions from your clinician. Our nocturia assessment guide covers the broader causes to investigate.